Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
University of Texas Medical School- Houston, Dept. of Psychiatry Mental Sciences Institute, Houston, Texas, United States
Yale University School of Medicine, New Haven, Connecticut, United States
Institute for Cognitive Studies, Tehran, Iran, Islamic Republic of
Yale University School of Medicine, New Haven, Connecticut, United States
Substance Abuse Research Center, Muar, Johor, Malaysia
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
University of Connecticut Health Center, Farmington, Connecticut, United States
· Center for Drug and Alcohol Programs,· Medical University of South Carolina, Charleston, South Carolina, United States
VA Connecticut Healthcare Systems, West Haven, Connecticut, United States
University of Minnesota, Minneapolis, Minnesota, United States
National Public Health Institute, Helsinki, Finland
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Tobacco Use Research Center, Philadelphia, Pennsylvania, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.